Open AccessPrognosis Varies by Intrinsic Tumor Subtype in Patients Treated with Ribociclib
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13660
Subject(s) - medicine , oncology , cancer , biomarker , endocrine system , clinical trial , breast cancer , hormone , biochemistry , chemistry
According to a new biomarker analysis of the MONALEESA trials, intrinsic tumor subtype is an important predictor of clinical outcomes in patients with HR‐positive/HER2‐negative breast cancer treated with ribociclib and endocrine therapy.